News coverage about Portola Pharmaceuticals (NASDAQ:PTLA) has been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.269608856499 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Several research analysts have issued reports on the company. Oppenheimer reiterated a “buy” rating and issued a $80.00 price target on shares of Portola Pharmaceuticals in a report on Wednesday, September 6th. BidaskClub upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Credit Suisse Group upgraded Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price target on the stock in a report on Wednesday, August 23rd. Morgan Stanley reiterated an “overweight” rating and issued a $81.00 price target (up previously from $75.00) on shares of Portola Pharmaceuticals in a report on Friday, October 6th. Finally, Goldman Sachs Group assumed coverage on Portola Pharmaceuticals in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. Portola Pharmaceuticals has an average rating of “Buy” and an average price target of $71.15.

Portola Pharmaceuticals (PTLA) traded down $2.55 during mid-day trading on Tuesday, hitting $49.23. The stock had a trading volume of 1,076,419 shares, compared to its average volume of 965,242. Portola Pharmaceuticals has a 52 week low of $17.74 and a 52 week high of $67.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. During the same quarter last year, the company earned ($1.64) earnings per share. The company’s revenue for the quarter was down 58.9% on a year-over-year basis. equities research analysts anticipate that Portola Pharmaceuticals will post -4.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Portola Pharmaceuticals (PTLA) Share Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.